抗HIV“重磅”药物拉米夫定有效中国专利分析及应对建议

Chinese patent analysis of anti-HIV drug lamivudine and suggestions

目前我国艾滋病流行形势严峻,而治疗HIV的主要药物研发技术均被国外制药企业所垄断。抗HIV病毒的"重磅"药物拉米夫定的核心专利在近期被无效,给制药企业带来了极好的发展机遇。本文对抗HIV病毒的"重磅"药物拉米夫定在国内尚在有效状态的专利进行分析,在此基础上为中国制药企业在相关药物的研发思路、专利保护与市场应用方面提供应对建议。

In our country, AIDS （acquired immune deficiency syndrome） is prevalent at present, but the key development technology of the main anti-HIV drugs is monopolized by foreign pharmaceutical companies. The patent of lamivudine, which is a ＂heavy bomb＂ drug for HIV virus, has been invalidated recently, and this brings the opportunities of development for domestic companies. In this paper, we analyze the domestic patent of lamivudi- ne which is in a valid state, and on this basis, provide some suggestions on the developing ideas, patent protection, and market application of related drugs for domestic companies.